
Avalo Therapeutics fell 62.0% from $17.74 to $6.75, behind the S&P 500's +9.7%. Its worst day was Oct 22 (−39.2%), and its low came Nov 5 at $6.63.
Nov 20, 2025 – Nov 19, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.48 beat the $-1.51 estimate on $59,000.00 revenue.
+0.6% · S&P 500 +1.1%
Avalo Therapeutics shares rose 18.0%, while the S&P 500 rose 0.8%.
Story events cover the past 12 months · Times ET
+18.0% · S&P 500 +0.8%
EPS of $-0.98 beat the $-1.01 estimate on $0.00 revenue.
−0.5% · S&P 500 +0.6%
Avalo Therapeutics shares rose 16.2%, while the S&P 500 fell 0.3%.
+16.2% · S&P 500 −0.3%
EPS of $-0.83 missed the $-0.63 estimate on $0.00 revenue.
−0.7% · S&P 500 −0.2%
Avalo Therapeutics shares fell 39.2%, while the S&P 500 fell 1.2%.
−39.2%, the year's worst day, on 26M shares, the year's heaviest volume · S&P 500 −1.2%
EPS of $-0.34 beat the $-0.56 estimate on $0.00 revenue.
−6.2% · S&P 500 −4.4%
Where it ended: a close of $6.75 on Nov 19, 2026.
Nothing in the past 12 months.
All AVTX dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for AVTX and SPY from Benzinga historical bars. Not investment advice.